Ep 56: Making Psychedelic Therapy Accessible with Myriam Barthes

Rachel speaks with Myriam Barthes, co-founder and CEO of Journey Clinical, the largest network of ketamine-assisted psychotherapy trained therapists in the United States. Journey Clinical operates as a collaborative care platform — connecting licensed psychotherapists with a dedicated medical team so that therapists can offer ketamine-assisted psychotherapy to their clients without having to navigate the medical side alone. Myriam came to this work through her own personal experience with ketamine-assisted psychotherapy, which she describes as transformative. Before co-founding Journey Clinical, she worked as an AI strategist and consultant — and she has brought that systems-thinking lens to one of the most complex problems in mental health: how do you take a treatment that is clinically promising, legally available, and genuinely hard to access, and make it actually reachable for patients and the therapists who want to offer it? The conversation focuses on the business and systems side of psychedelic-assisted therapy — how Journey Clinical works, what it actually takes for a licensed therapist to start offering KAP, and what the regulatory landscape looks like right now. Myriam walks Rachel through the collaborative care model, what happens when a client goes through a ketamine session, and why the therapeutic relationship before and after the medicine is as important as the medicine itself. She also shares her perspective on where the field is heading as psilocybin moves closer to FDA approval — and why she believes the infrastructure being built now for ketamine will matter enormously for what comes next. This episode pairs well with our conversation with Will Ratliff of Transcend Health Solutions, which goes deeper into the clinical and medical side of ketamine-assisted psychotherapy. Resources Mentioned Articles Referenced: FDA Moves to Fast-Track Review of Psilocybin and Methylone for Mental Health — CNN (April 2026): https://www.cnn.com/2026/04/24/health/fda-psychedelic-drugs-priority-vouchers What Psychedelics Reveal About the Human Capacity for Healing — Myriam Barthes, Journey Clinical (May 2026) Note: written by guest, published on guest's organization website: https://www.journeyclinical.com/resources/what-psychedelics-reveal-about-the-human-capacity-for-healing Considerations for Potential Future Therapeutic Use of Psychedelic Drugs — FDA/Federal Register (July 2026): https://www.federalregister.gov/documents/2026/07/14/2026-14155/considerations-for-potential-future-therapeutic-use-of-psychedelic-drugs-public-hearing-request-for Psychedelic Drugs and Mental Health — CNBC (July 2026): https://www.cnbc.com/2026/07/19/psychedelic-drugs-mental-health.html Connect with Myriam Barthes: Journey Clinical: https://www.journeyclinical.com Connect with The Mental Health Evolution: Website: https://www.traumaspecialiststraining.com/mental-health-evolution-podcast Instagram: /thementalhealthevolution/ LinkedIn: /the-mental-health-evolution Facebook: /TheMentalHealthEvolution Music by Zach Harrison